Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Dirofilariasis: a parasitic cause of subcutaneous nodule.

Wendum D, Campa P, Develoux M, Zmuda M, Putterman M, Hennequin C.

Clin Microbiol Infect. 2019 Jun 20. pii: S1198-743X(19)30340-4. doi: 10.1016/j.cmi.2019.06.015. [Epub ahead of print] No abstract available.

PMID:
31229594
2.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
3.

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.

Valin N, Fonquernie L, Daguenel A, Campa P, Anthony T, Guiguet M, Girard PM, Meyohas MC.

BMC Infect Dis. 2016 Nov 29;16(1):718.

4.

CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden.

Chevalier MF, Didier C, Girard PM, Manea ME, Campa P, Barré-Sinoussi F, Scott-Algara D, Weiss L.

Front Immunol. 2016 Sep 29;7:395. eCollection 2016.

5.

Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study.

Bottero J, Boyd A, Gozlan J, Carrat F, Lemoine M, Rougier H, Varsat B, Boo N, Charlois-Ou C, Collignon A, Cha O, Campa P, Dhotte P, Girard PM, Lacombe K.

Eur J Gastroenterol Hepatol. 2016 Jun;28(6):633-9. doi: 10.1097/MEG.0000000000000620.

PMID:
26954517
6.

Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.

Weiss L, Chevalier MF, Assoumou L, Paul JL, Alhenc-Gelas M, Didier C, Taibi S, Manea EM, Campa P, Girard PM, Costagliola D; IMEA 043-CESAR trial working group.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):390-8. doi: 10.1097/QAI.0000000000000879.

PMID:
26536319
7.

Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country.

Bourgarit A, Baron G, Breton G, Tattevin P, Katlama C, Allavena C, Campa P, Ravaud P, Lortholary O, Carcelain G; IGRAVIH Study Group.

Ann Am Thorac Soc. 2015 Aug;12(8):1138-45. doi: 10.1513/AnnalsATS.201412-600OC. Erratum in: Ann Am Thorac Soc. 2016 Apr;13(4):576.

PMID:
26213798
8.

High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics.

Ruppé E, Armand-Lefèvre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y, Goujon C, Ralaimazava P, Campa P, Girard PM, Wyplosz B, Vittecoq D, Bouchaud O, Le Loup G, Pialoux G, Perrier M, Wieder I, Moussa N, Esposito-Farèse M, Hoffmann I, Coignard B, Lucet JC, Andremont A, Matheron S.

Clin Infect Dis. 2015 Aug 15;61(4):593-600. doi: 10.1093/cid/civ333. Epub 2015 Apr 22.

PMID:
25904368
9.

Metabolic disorders and cardiovascular risk in treatment-naive HIV-infected patients of sub-saharan origin starting antiretrovirals: impact of westernized lifestyle.

Eholié SP, Lacombe K, Krain A, Diallo Z, Ouiminga M, Campa P, Bouchaud O, Bissagnene E, Girard PM.

AIDS Res Hum Retroviruses. 2015 Apr;31(4):384-92. doi: 10.1089/AID.2014.0164. Epub 2015 Mar 17.

PMID:
25707418
10.

Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.

Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S.

Clin Infect Dis. 2015 May 15;60(10):1521-7. doi: 10.1093/cid/civ124. Epub 2015 Feb 17.

PMID:
25690598
11.

Chronic Schistosoma mekongi in a traveler--a case report and review of the literature.

Campa P, Develoux M, Belkadi G, Magne D, Lame C, Carayon MJ, Girard PM.

J Travel Med. 2014 Sep-Oct;21(5):361-3. doi: 10.1111/jtm.12137. Epub 2014 Jun 9.

12.

Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region.

Bottero J, Boyd A, Lemoine M, Carrat F, Gozlan J, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Valin N, Nau J, Campa P, Silbermann B, Bary M, Girard PM, Lacombe K.

PLoS One. 2014 Mar 24;9(3):e92266. doi: 10.1371/journal.pone.0092266. eCollection 2014.

13.

CD8 transverse myelitis in a patient with HIV-1 infection.

Moulignier A, Lescure FX, Savatovsky J, Campa P.

BMJ Case Rep. 2014 Feb 6;2014. pii: bcr-2013-201073. doi: 10.1136/bcr-2013-201073.

14.

Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases.

Cordel H, Cailhol J, Matheron S, Bloch M, Godineau N, Consigny PH, Gros H, Campa P, Bourée P, Fain O, Ralaimazava P, Bouchaud O.

Malar J. 2013 Nov 7;12:399. doi: 10.1186/1475-2875-12-399.

15.

The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation.

Chevalier MF, Petitjean G, Dunyach-Rémy C, Didier C, Girard PM, Manea ME, Campa P, Meyer L, Rouzioux C, Lavigne JP, Barré-Sinoussi F, Scott-Algara D, Weiss L.

PLoS Pathog. 2013;9(6):e1003453. doi: 10.1371/journal.ppat.1003453. Epub 2013 Jun 20.

16.

Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France.

Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, Boo N, Dhotte P, Varsat B, Muller G, Cha O, Picard O, Nau J, Campa P, Silbermann B, Bary M, Girard PM, Lacombe K.

J Hepatol. 2013 Mar;58(3):473-8. doi: 10.1016/j.jhep.2012.11.016. Epub 2012 Nov 23.

PMID:
23183527
17.

Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients.

Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda JD, Meynard JL, Poirot JL, Fonquernie L, Girard PM.

J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):360-7. doi: 10.1097/QAI.0b013e318249de59.

PMID:
22267015
18.

Level of double negative T cells, which produce TGF-β and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection.

Petitjean G, Chevalier MF, Tibaoui F, Didier C, Manea ME, Liovat AS, Campa P, Müller-Trutwin M, Girard PM, Meyer L, Barré-Sinoussi F, Scott-Algara D, Weiss L.

AIDS. 2012 Jan 14;26(2):139-48. doi: 10.1097/QAD.0b013e32834e1484.

PMID:
22045342
19.

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05).

Antivir Ther. 2011;16(6):937-40. doi: 10.3851/IMP1826.

PMID:
21900727
20.

[Travel in tropical countries].

Poirot JL, Campa P.

Rev Prat. 2011 Apr;61(4):551-8. French. No abstract available.

PMID:
21548244
21.

How to improve the quality of a disease management program for HIV-infected patients using a computerized data system. The Saint-Antoine Orchestra program.

Fonquernie F, Lacombe K, Vincensini JP, Boccara F, Clozel S, Ayouch Boda A, Bollens D, Campa P, Pacanowski J, Meynard JL, Meyohas MC, Girard PM.

AIDS Care. 2010 May;22(5):588-96. doi: 10.1080/09540120903280893.

PMID:
20401768
22.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.

Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S; ANRS CO5 HIV-2 Cohort Study Group.

AIDS. 2009 Jun 1;23(9):1171-3. doi: 10.1097/QAD.0b013e32832949f0.

PMID:
19349850
23.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20.

PMID:
18718922
24.

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Antimicrob Agents Chemother. 2008 Apr;52(4):1545-8. doi: 10.1128/AAC.01284-07. Epub 2008 Jan 28.

25.

[Early diagnosis and prevention of comorbidities among HIV-infected patients: the Orchestra Saint-Antoine Program].

Fonquernie L, Clozel S, Vincensini JP, Boccara F, Rousselle B, Pitard C, Bollens D, Campa P, Pacanowski J, Lacombe K, Meynard JL, Meyohas MC, Girard PM.

Med Mal Infect. 2007 Dec;37 Suppl 3:S229-36. Epub 2007 Nov 7. French.

PMID:
17997254
26.

No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort.

Descamps D, Damond F, Bénard A, Matheron S, Campa P, Taieb A, Yahyaoui R, Chêne G, Brun-Vézinet F.

AIDS. 2006 Apr 24;20(7):1076-9.

PMID:
16603866
27.

CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.

Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G; ANRS CO5 HIV2 Cohort Study Group.

AIDS. 2006 Feb 14;20(3):459-62.

PMID:
16439883
28.

Proliferative, IFNgamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection.

Alatrakchi N, Damond F, Matheron S, Beretta-Tempelhoff S, Campa P, Carcelain G, Brun-Vezinet F, Autran B; French HIV-2 study group.

AIDS. 2006 Jan 2;20(1):29-34.

PMID:
16327316
29.

Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.

Damond F, Collin G, Matheron S, Peytavin G, Campa P, Delarue S, Taieb A, Bénard A, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 5 VIH-2).

Antivir Ther. 2005;10(7):861-5.

PMID:
16312183
30.

Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.

Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F.

J Clin Microbiol. 2005 Aug;43(8):4234-6.

31.

Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D.

J Clin Microbiol. 2005 Jan;43(1):484-7.

32.

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.

Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, Delaunay C, Chêne G, Brun-Vézinet F, Descamps D.

Antivir Ther. 2004 Aug;9(4):635-6. No abstract available.

PMID:
15456096
33.

High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.

Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, Pueyo S, Chêne G, Brun-Vézinet F; French ANRS HIV-2 Cohort Study Group.

J Med Virol. 2004 Oct;74(2):197-201.

PMID:
15332266
34.

Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification.

Damond F, Worobey M, Campa P, Farfara I, Colin G, Matheron S, Brun-Vézinet F, Robertson DL, Simon F.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):666-72.

PMID:
15242544
35.

Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.

Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, Salamon R, Chêne G, Brun-Vezinet F; French HIV-2 Cohort Study Group.

AIDS. 2003 Dec 5;17(18):2593-601.

PMID:
14685053
36.

Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections.

Damond F, Gueudin M, Pueyo S, Farfara I, Robertson DL, Descamps D, Chène G, Matheron S, Campa P, Brun-Vézinet F, Simon F.

J Clin Microbiol. 2002 Oct;40(10):3654-9.

37.

PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population.

Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G.

Eur J Clin Invest. 2002 Jan;32(1):9-15.

PMID:
11851721
38.

Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR.

Damond F, Descamps D, Farfara I, Telles JN, Puyeo S, Campa P, Leprêtre A, Matheron S, Brun-Vezinet F, Simon F.

J Clin Microbiol. 2001 Dec;39(12):4264-8.

39.

The common mutations in the lipoprotein lipase gene in Italy: effects on plasma lipids and angiographically assessed coronary atherosclerosis.

Arca M, Campagna F, Montali A, Barillà F, Mangieri E, Tanzilli G, Seccareccia F, Campa PP, Ricci G, Pannitteri G.

Clin Genet. 2000 Nov;58(5):369-74.

PMID:
11140837
40.

Physical activity and coronary collateral circulation.

Barillà F, Mangieri E, Tanzilli G, Prosseda L, Campa PP.

Ital Heart J. 2000 Sep;1 Suppl 3:S72-4. No abstract available.

PMID:
11003031
41.

Adenosine triphosphate-dependent potassium channel modulation and cardioplegia-induced protection of human atrial muscle in an in vitro model of myocardial stunning.

Monti F, Iwashiro K, Picard S, Criniti A, La Francesca S, Ruvolo G, Papalia U, Campa PP, Marino B, Puddu PE.

J Thorac Cardiovasc Surg. 2000 Apr;119(4 Pt 1):842-8.

42.

A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease.

Baroni MG, D'Andrea MP, Montali A, Pannitteri G, Barillà F, Campagna F, Mazzei E, Lovari S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M.

Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2975-80.

PMID:
10591678
43.

Cicletanine prevents the excitation-conduction blocks induced by terfenadine in ischemic myocardium.

Criniti A, Picard S, Monti F, Dawodu AA, Ruvolo G, Puddu PE, Campa PP.

Eur J Pharmacol. 1999 Oct 15;382(3):197-205.

PMID:
10556670
44.

Enoximone coupled to very low dose dobutamine echocardiography detects myocardial viability in akinetic and dyskinetic post-myocardial infarcted areas.

Mangieri E, Alessandri N, Tanzilli G, Barillà F, Puddu PE, Monti F, Canale G, Campa PP.

Am J Cardiol. 1999 Aug 1;84(3):264-9.

PMID:
10496433
45.

Blood pressure circadian rhythm and variability in subjects with severe heart failure.

Moroni C, De Biase L, Pannarale G, Bondanini F, Affricano D, Campa PP, Cassone R.

Blood Press. 1998 Nov;7(5-6):282-5.

PMID:
10321440
46.

[Left ventricular aneurysm in a patient with mildly dilated cardiomyopathy].

De Biase L, Berni A, Giorda GP, Grutter G, Nigri A, Campa PP.

Cardiologia. 1999 Feb;44(2):191-2. Italian.

PMID:
10208057
47.

Recovery of contractility of viable myocardium during inotropic stimulation is not dependent on an increase of myocardial blood flow in the absence of collateral filling.

Barillà F, De Vincentis G, Mangieri E, Ciavolella M, Panitteri G, Scopinaro F, Critelli G, Campa PP.

J Am Coll Cardiol. 1999 Mar;33(3):697-704.

48.

[Natural harmonic echocardiography].

Voci P, Plaustro G, Testa G, Campa PP.

Cardiologia. 1998 Sep;43(9):947-51. Italian.

PMID:
9859609
49.

Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging.

Gaudio C, Tanzilli G, Ferri FM, Villatico Campbell S, Bertocchi F, Motolese M, Campa PP.

J Cardiovasc Pharmacol. 1998 Nov;32(5):760-8.

PMID:
9821850
50.

[Arterial hypertension, non-drug treatment and cardiovascular risk].

Blacher J, Tartiere JM, Amah G, Campa P, Raison J, Safar M.

Ann Cardiol Angeiol (Paris). 1998 Feb;47(2):81-5. French.

PMID:
9772933

Supplemental Content

Support Center